🚀 VC round data is live in beta, check it out!
Milestone Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Milestone Pharmaceuticals and similar public comparables like Arcturus Therapeutics, Eledon Pharmaceuticals, Binex, Camp4 Therapeutics and more.
Milestone Pharmaceuticals Overview
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Founded
2003
HQ
Employees
33
Website
Sectors
Financials (LTM)
EV
$190M
Milestone Pharmaceuticals Financials
Milestone Pharmaceuticals reported last 12-month revenue of $14M.
In the same LTM period, Milestone Pharmaceuticals generated $14M in gross profit and had net loss of ($58M).
Revenue (LTM)
Milestone Pharmaceuticals P&L
In the most recent fiscal year, Milestone Pharmaceuticals reported revenue of $2M and EBITDA of ($59M).
Milestone Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $14M | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | $14M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($59M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3823%) | XXX | XXX | XXX |
| EBIT Margin | (417%) | XXX | (4019%) | XXX | XXX | XXX |
| Net Profit | ($58M) | XXX | ($63M) | XXX | XXX | XXX |
| Net Margin | (423%) | XXX | (4079%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Milestone Pharmaceuticals Stock Performance
Milestone Pharmaceuticals has current market cap of $238M, and enterprise value of $190M.
Market Cap Evolution
Milestone Pharmaceuticals' stock price is $2.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $190M | $238M | 0.2% | XXX | XXX | XXX | $-0.54 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMilestone Pharmaceuticals Valuation Multiples
Milestone Pharmaceuticals trades at 13.8x EV/Revenue multiple, and (3.2x) EV/EBITDA.
EV / Revenue (LTM)
Milestone Pharmaceuticals Financial Valuation Multiples
As of April 11, 2026, Milestone Pharmaceuticals has market cap of $238M and EV of $190M.
Equity research analysts estimate Milestone Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Milestone Pharmaceuticals has a P/E ratio of (4.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $238M | XXX | $238M | XXX | XXX | XXX |
| EV (current) | $190M | XXX | $190M | XXX | XXX | XXX |
| EV/Revenue | 13.8x | XXX | 123.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (3.2x) | XXX | XXX | XXX |
| EV/EBIT | (3.3x) | XXX | (3.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 14.0x | XXX | — | XXX | XXX | XXX |
| P/E | (4.1x) | XXX | (3.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Milestone Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Milestone Pharmaceuticals Margins & Growth Rates
Milestone Pharmaceuticals' revenue in the last 12 month grew by 198%.
Milestone Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.9M for the same period.
Milestone Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 198% | XXX | 2861% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3823%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 271% | XXX | 1831% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 128% | XXX | 1117% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 131% | XXX | 1171% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 4119% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Milestone Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Arcturus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Eledon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Binex | XXX | XXX | XXX | XXX | XXX | XXX |
| Camp4 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Procaps Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Milestone Pharmaceuticals M&A Activity
Milestone Pharmaceuticals acquired XXX companies to date.
Last acquisition by Milestone Pharmaceuticals was on XXXXXXXX, XXXXX. Milestone Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Milestone Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMilestone Pharmaceuticals Investment Activity
Milestone Pharmaceuticals invested in XXX companies to date.
Milestone Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Milestone Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Milestone Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Milestone Pharmaceuticals
| When was Milestone Pharmaceuticals founded? | Milestone Pharmaceuticals was founded in 2003. |
| Where is Milestone Pharmaceuticals headquartered? | Milestone Pharmaceuticals is headquartered in Canada. |
| How many employees does Milestone Pharmaceuticals have? | As of today, Milestone Pharmaceuticals has over 33 employees. |
| Who is the CEO of Milestone Pharmaceuticals? | Milestone Pharmaceuticals' CEO is Joseph G. Oliveto. |
| Is Milestone Pharmaceuticals publicly listed? | Yes, Milestone Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Milestone Pharmaceuticals? | Milestone Pharmaceuticals trades under MIST ticker. |
| When did Milestone Pharmaceuticals go public? | Milestone Pharmaceuticals went public in 2019. |
| Who are competitors of Milestone Pharmaceuticals? | Milestone Pharmaceuticals main competitors are Arcturus Therapeutics, Eledon Pharmaceuticals, Binex, Camp4 Therapeutics. |
| What is the current market cap of Milestone Pharmaceuticals? | Milestone Pharmaceuticals' current market cap is $238M. |
| What is the current revenue of Milestone Pharmaceuticals? | Milestone Pharmaceuticals' last 12 months revenue is $14M. |
| What is the current revenue growth of Milestone Pharmaceuticals? | Milestone Pharmaceuticals revenue growth (NTM/LTM) is 198%. |
| What is the current EV/Revenue multiple of Milestone Pharmaceuticals? | Current revenue multiple of Milestone Pharmaceuticals is 13.8x. |
| Is Milestone Pharmaceuticals profitable? | No, Milestone Pharmaceuticals is not profitable. |
| What is the current net income of Milestone Pharmaceuticals? | Milestone Pharmaceuticals' last 12 months net income is ($58M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.